IDEXX Laboratories (IDXX)
(Real Time Quote from BATS)
$506.87 USD
+0.13 (0.03%)
Updated Sep 23, 2024 01:22 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for IDEXX Laboratories, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 454 | 113 | 144 | 384 | 90 |
Receivables | 457 | 401 | 368 | 331 | 269 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 380 | 368 | 269 | 210 | 195 |
Other Current Assets | 204 | 220 | 174 | 138 | 125 |
Total Current Assets | 1,495 | 1,101 | 956 | 1,063 | 680 |
Net Property & Equipment | 702 | 649 | 588 | 555 | 534 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 450 | 459 | 458 | 296 | 298 |
Deposits & Other Assets | 497 | 418 | 330 | 290 | 240 |
Total Assets | 3,260 | 2,747 | 2,437 | 2,295 | 1,832 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 250 | 579 | 74 | 0 | 289 |
Accounts Payable | 111 | 110 | 116 | 75 | 72 |
Current Portion Long-Term Debt | 75 | 75 | 75 | 50 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 479 | 434 | 459 | 416 | 323 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 37 | 38 | 40 | 43 | 41 |
Total Current Liabilities | 952 | 1,236 | 764 | 583 | 725 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 36 | 39 | 50 | 58 | 82 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 623 | 694 | 775 | 858 | 699 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 66 | 68 | 71 | 86 | 81 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,775 | 2,138 | 1,747 | 1,662 | 1,655 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 11 | 11 | 11 | 11 | 11 |
Capital Surplus | 1,570 | 1,463 | 1,377 | 1,295 | 1,214 |
Retained Earnings | 4,445 | 3,600 | 2,920 | 2,176 | 1,596 |
Other Equity | -66 | -73 | -48 | -48 | -41 |
Treasury Stock | 4,475 | 4,392 | 3,571 | 2,800 | 2,601 |
Total Shareholder's Equity | 1,485 | 609 | 690 | 633 | 178 |
Total Liabilities & Shareholder's Equity | 3,260 | 2,747 | 2,437 | 2,295 | 1,832 |
Total Common Equity | 1,485 | 609 | 690 | 633 | 178 |
Shares Outstanding | 83.00 | 82.80 | 84.70 | 85.30 | 85.70 |
Book Value Per Share | 17.89 | 7.35 | 8.15 | 7.42 | 2.08 |
Fiscal Year End for IDEXX Laboratories, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 402 | 397 | 454 | 332 | 133 |
Receivables | 534 | 507 | 457 | 453 | 462 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 380 | 391 | 380 | 394 | 395 |
Other Current Assets | 213 | 207 | 204 | 206 | 189 |
Total Current Assets | 1,529 | 1,502 | 1,495 | 1,384 | 1,179 |
Net Property & Equipment | 708 | 709 | 702 | 687 | 683 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 519 | 524 | 450 | 449 | 455 |
Deposits & Other Assets | 540 | 499 | 497 | 448 | 439 |
Total Assets | 3,415 | 3,354 | 3,260 | 3,086 | 2,871 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 250 | 250 | 250 | 250 | 264 |
Accounts Payable | 117 | 117 | 111 | 113 | 108 |
Current Portion Long-Term Debt | 170 | 75 | 75 | 150 | 75 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 541 | 476 | 479 | 420 | 399 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 38 | 38 | 37 | 37 | 38 |
Total Current Liabilities | 1,117 | 957 | 952 | 970 | 884 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 37 | 37 | 36 | 38 | 35 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 525 | 621 | 623 | 619 | 697 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 53 | 66 | 60 | 64 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,835 | 1,785 | 1,775 | 1,789 | 1,777 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 11 | 11 | 11 | 11 | 11 |
Capital Surplus | 1,625 | 1,605 | 1,570 | 1,543 | 1,515 |
Retained Earnings | 4,883 | 4,680 | 4,445 | 4,250 | 4,038 |
Other Equity | -79 | -75 | -66 | -69 | -68 |
Treasury Stock | 4,860 | 4,652 | 4,475 | 4,437 | 4,402 |
Total Shareholder's Equity | 1,580 | 1,569 | 1,485 | 1,297 | 1,094 |
Total Liabilities & Shareholder's Equity | 3,415 | 3,354 | 3,260 | 3,086 | 2,871 |
Total Common Equity | 1,580 | 1,569 | 1,485 | 1,297 | 1,094 |
Shares Outstanding | 82.50 | 82.50 | 83.00 | 83.00 | 83.00 |
Book Value Per Share | 19.15 | 19.02 | 17.89 | 15.63 | 13.18 |